Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular
complications, which represent the major cause of mortality. Despite effective treatment of …

Diabetes mellitus is one of the most common chronic medical conditions, and is a risk factor
for the development of atrial fibrillation (AF). The presence of diabetes in patients with AF is …

Importance Type 2 diabetes is associated with increased cardiovascular risk. In placebo-
controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin …

Dipeptidyl peptidase-4 (DPP-4), also known as the T-cell antigen CD26, is a multi-functional
protein which, besides its catalytic activity, also functions as a binding protein and a ligand …

Importance Phase 3 trials have not compared oral semaglutide, a glucagon-like peptide 1
receptor agonist, with other classes of glucose-lowering therapy. Objective To compare …

GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …

Introduction: Diabetic kidney disease (DKD) is a major cause of morbidity and mortality in
diabetes and is the most common cause of proteinuric and non-proteinuric forms of end …

Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease
(ESRD) and is therefore a major burden on the healthcare system. Patients with DKD are …

Background In patients with type 2 diabetes, intensive glucose control can be renoprotective
and albuminuria-lowering treatments can slow the deterioration of kidney function. We …

Background Globally, diabetic kidney disease (DKD) is the leading cause of end-stage renal
disease. As the most common microvascular complication of diabetes, DKD is a thorny …